LIVINGSTONE HEALTH HOLDINGS LIMITED

(Incorporated in the Republic of Singapore)
(Company Registration Number 200404283C)

RECEIPT OF LISTING AND QUOTATION NOTICE

---

*Unless otherwise defined herein or the context requires otherwise, all capitalised terms used in this announcement shall have the same meanings ascribed to them in the Company's announcement on the Proposed Internal Reorganisation of Subsidiaries and Acquisition of Phoenix Medical Group dated 15 July 2024 (the "**Announcement**").*

The Board of Directors (the "**Board**") of Livingstone Health Holdings Limited (the "**Company**" and together with its subsidiaries, the "**Group**") refers to the Announcement relating to, *inter alia*, the Proposed Acquisition.

The Board wishes to announce that the Company had, on 24 July 2024, received the listing and quotation notice from the SGX-ST (the "**LQN**"), for the listing and quotation of 47,616,465 new shares in the capital of the Company, to be issued pursuant to the Proposed Acquisition (the "**Consideration Shares**"). The listing and quotation of the Consideration Shares are subject to the Company's compliance with the SGX-ST's listing requirements.

The allotment and issuance of the Consideration Shares will be made pursuant to the authority to be granted by the Shareholders under the general share issue mandate at the AGM of the Company to be held on 31 July 2024 (the "**General Mandate**"). The Company will be seeking approval of Shareholders on its General Mandate at the AGM to be held on 31 July 2024.

The LQN is not to be taken as an indication of the merits of the Proposed Acquisition, the Consideration Shares, the Company and/or its subsidiaries.

The Company will make further announcement(s) to keep shareholders informed, as and when there are further updates or developments on, *inter alia*, the Proposed Acquisitions, in due course.

By Order of the Board
Livingstone Health Holdings Limited

Dr Tay Ching Yit, Wilson
Executive Director and Chief Executive Officer

25 July 2024

---

*This announcement has been reviewed by the Company's Sponsor, SAC Capital Private Limited (the **"Sponsor"**). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Lee Khai Yinn (Telephone: (65) 6232 3210) at 1 Robinson Road, #21-00, AIA Tower, Singapore 048542.